|Karolinska Development AB -- Sweden Stock|| |
SEK 5.40 0.20 3.57%
Chairman of the Board
Dr. Bo Jesper Hansen M.D. Ph.D. was Independent Chairman of the Board of Karolinska Development AB since October 1 2013. He is Member of the Asian Committee and Chairman of Remuneration and Audit Committees. He was Director of the Company since May 14 2013. He is also Chairman of Swedish Orphan Biovitrum AB and Board member of GenSpera Inc. Newron SA Ablynx NV Orphazyme AS and CMC Kontrast AB. His previous appointments include various positions in Swedish Orphan International AB since 1993 including CEO . He was Medical advisor for Synthelabo Pfizer Pharmacia and Yamanouchi. He is Founder of Scandinavian Medical Research.
Age: 57 Chairman Since 2013 Ph.D
46 8 52 48 60 70 http://www.karolinskadevelopment.com
The company has return on total asset (ROA)
of (3.86) %
which means that it has lost $3.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of 120.96 %
meaning that it generated $120.96 on every $100 dollars invested by stockholders.
The company has accumulated 379.18 M in total debt with debt to equity ratio (D/E) of 141.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 13.84 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Karolinska Development AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB was founded in 2003 and is headquartered in Stockholm, Sweden. Karolinska Development operates under Pharmaceuticals And Biosciences classification in Sweden and traded on Stockholm Stock Exchange exchange.Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Tomtebodav?gen 23 A and employs 13 people.